Literature DB >> 30155257

Prostate cancer leading to monoclonal gammopathy of undetermined significance: A case report.

Waqas Jehangir1, Sunil Tulpule1, Federico Sanabria2, Harsh Bhatt2, Shoaib Zafar1, Mohamed Osman1, Souad Enakuaa1, Abdalla Yousif1.   

Abstract

Prostate cancer is one of the most common cancer types, affecting millions of individuals worldwide. The present study reported two cases of metastatic prostate cancer presenting with newly diagnosed monoclonal gammopathy of undetermined significance (MGUS). To the best of our knowledge, prostate cancer leading to MGUS has not been documented previously. MGUS is generally thought to be benign and has been demonstrated to convert into multiple myeloma (MM), as well as other lymphoproliferative disorders. Due to the high mortality rate associated with MM, further studies are required to confirm and clarify the association between prostate cancer and MGUS. Additionally, patients can be counseled on the requirement for follow up studies following a diagnosis of prostate cancer.

Entities:  

Keywords:  MGUS; lymphoproliferative disorders; multiple myeloma; prostate cancer

Year:  2018        PMID: 30155257      PMCID: PMC6109677          DOI: 10.3892/mco.2018.1674

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  11 in total

Review 1.  Clinical practice. Monoclonal gammopathy of undetermined significance.

Authors:  Joan Bladé
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

Review 2.  Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Oncology (Williston Park)       Date:  2011-06       Impact factor: 2.990

3.  [A case of prostate cancer associated with osteolytic bone metastases].

Authors:  T Migita; K Maeda; N Ogata
Journal:  Hinyokika Kiyo       Date:  1999-05

4.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

5.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

6.  Prostatic cancer presenting monoclonal gammopathy: report of two cases.

Authors:  M Tsutsumi; T Hara; R Fukasawa; K Koiso
Journal:  Hinyokika Kiyo       Date:  1993-06

7.  Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.

Authors:  R A Kyle
Journal:  Am J Med       Date:  1978-05       Impact factor: 4.965

8.  [Prostate adenocarcinoma and synchcronous multiple myeloma: a case report].

Authors:  M E Pérez López; J García Mata; J García Gómez; M Salgado Fernández; J L Fírvida Pérez
Journal:  Actas Urol Esp       Date:  2007-02       Impact factor: 0.994

Review 9.  Prostate cancer and the influence of dietary factors and supplements: a systematic review.

Authors:  Dalvinder Mandair; Roberta Elisa Rossi; Marinos Pericleous; Tara Whyand; Martyn Evan Caplin
Journal:  Nutr Metab (Lond)       Date:  2014-06-16       Impact factor: 4.169

Review 10.  From bench to bedside: the realities of reducing global prostate cancer disparity in black men.

Authors:  Robin Roberts
Journal:  Ecancermedicalscience       Date:  2014-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.